Management of Neonatal Hyperbilirubinemia

Assessment and Diagnosis

The American Academy of Pediatrics recommends assessing for high-risk scenarios that would change management, including hemolytic disease and acute bilirubin encephalopathy, in infants with neonatal hyperbilirubinemia 1, 2, 3, 4
Check for signs of ongoing hemolysis, such as rapid bilirubin rise, pallor, and hepatosplenomegaly, and obtain blood type and Coombs test if not already done 2, 3
Assess neurological status for signs of acute bilirubin encephalopathy, such as lethargy, poor feeding, high-pitched cry, altered tone, and opisthotonus 1, 3, 4

Phototherapy is generally not indicated in healthy term infants at 8 days of age with a bilirubin level of 18.4 mg/dL, but may still be indicated in infants with hemolytic disease or other high-risk factors 1, 2
The American Academy of Pediatrics recommends intensive phototherapy for infants with high-risk features, using special blue light with irradiance ≥30 μW/cm²/nm 2, 3, 4
Exchange transfusion is recommended for infants with total serum bilirubin ≥25 mg/dL at any time, or with signs of acute bilirubin encephalopathy 3, 4

Arrange follow-up within 24-48 hours for weight check and clinical assessment, and obtain repeat bilirubin measurement within 24-48 hours to ensure downward trend 1, 2
Transcutaneous bilirubin can be used if ≥24 hours have passed since phototherapy was stopped 2